A recent study published in JAMA found that as the acquisition prices of bevacizumab, rituximab, and trastuzumab fell from 2020 to 2024, hospitals’ profits on each biosimilar purchase increased, and the uptake of these oncology biosimilars rose quickly. This could be an important lesson for the upcoming Keytruda and Opdivo biosimilar launches. Researchers from the … Continue reading As Oncology Biosimilar Acquisition Prices Fall for Hospitals, Biosimilar Adoption Rises